Rigel Pharma (RIGL) – Hot FDA News
-
Rigel Pharma (RIGL) Announces U.S. FDA Approval of REZLIDHIA for Treatment of Adult Patients with R/R Acute Myeloid Leukemia with Susceptible IDH1 Mutation
-
FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
-
-
-
-
-
-
-
-
-
Back to RIGL Stock Lookup